Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | FDPS | P14324 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 2/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21712836 | 0.91 | FDPS (0.42) | FDPSEPHX1CES2SMPD1 | |
| SCHEMBL4635634 | 0.91 | FDPS (0.41) | CA1CA2FDPSALDH1A1LMNA | |
| SCHEMBL19685191 | 0.86 | LMNA (0.41) | CA1CA2FDPSALDH1A1LMNA | |
| SCHEMBL7763609 | 0.86 | LMNA (0.43) | CA1CA2FDPSALDH1A1LMNA | |
| SCHEMBL19155398 | 0.84 | FDPS (0.44) | FDPSCES2SMPD1 | |
| SCHEMBL18710346 | 0.84 | FDPS (0.44) | FDPSCES2SMPD1 | |
| SCHEMBL4635906 | 0.84 | FDPS (0.43) | CA1CA2FDPSCES2SMPD1 | |
| SCHEMBL15066539 | 0.83 | FDPS (0.36) | CA1CA2FDPSALDH1A1LMNA | |
| SCHEMBL20746483 | 0.82 | FDPS (0.45) | FDPSCES2SMPD1 | |
| SCHEMBL20746314 | 0.82 | FDPS (0.45) | FDPSCES2SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023067273-A1 | CYCLIC AMINE MONOAMIDES FOR THE EXTRACTION OF URANIUM(VI) AND PLUTONIUM(IV) AND FOR THE SEPARATION THEREOF WITHOUT REDUCTION OF THE PLUTONIUM(IV) | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2023-04-27 | — | — | WO | disclosed |
| CN-105971571-B | Method and composition for oil well and/or gas well | 弗洛泰克化学有限责任公司 | 2019-10-15 | — | — | CN | disclosed |
| CN-106837217-B | For oil well and/or the composition and method comprising terpenol of gas well | 弗洛泰克化学有限责任公司 | 2019-07-02 | — | — | CN | disclosed |
| CN-105419750-B | Method and composition for oil well and/or gas well | 弗洛泰克化学有限责任公司 | 2019-03-22 | — | — | CN | disclosed |
| EP-2872590-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2018-11-14 | — | — | EP | disclosed |
| US-20170349536-A1 | Natural Oil Derivatives Including (Meth)acrylate Functional Groups | ELEVANCE RENEWABLE SCIENCES, INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-9837622-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-05 | — | — | US | disclosed |
| US-9837622-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-05 | — | — | US | disclosed |
| US-9714214-B2 | Natural oil derivatives including (meth)acrylate functional groups | ELEVANCE RENEWABLE SCIENCES, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| CN-106837217-A | For oil well and/or the composition comprising terpenol and method of gas well | 弗洛泰克化学有限责任公司 | 2017-06-13 | — | — | CN | disclosed |
| EP-2025671-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2009-02-18 | — | — | EP | disclosed |
| US-20090023939-A1 | ALPHA-SUBSTITUTED VINYLTIN COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1947101-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-7351841-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| EP-1845090-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
| EP-1819692-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
| CN-1798739-A | 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators | NISSAN CHEMICAL IND LTD (JP) | 2006-07-05 | — | — | CN | disclosed |
| WO-2006062240-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2006-06-15 | — | — | WO | disclosed |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NR2C2, ROR1, NR0B2 | CA1 2516/4885CA2 2631/4885FDPS 3051/4885 |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | CA1 2676/4885CA2 2832/4885FDPS 3141/4885 |
| US-20170349536-A1 | Natural Oil Derivatives Including (Meth)acrylate Functional Groups | ACR, FASN, C3AR1 | CA1 4749/4885CA2 4746/4885FDPS 589/4885 |
| US-20090023939-A1 | ALPHA-SUBSTITUTED VINYLTIN COMPOUND | TST, CCNT1, TMT1A | CA1 2218/4885CA2 1845/4885FDPS 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.